%0 Journal Article %A M. Markman %T What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer? %D 2008 %R 10.1111/j.1525-1438.2007.01103.x %J International Journal of Gynecologic Cancer %P 36-39 %V 18 %N Suppl 1 %X Three well-designed and conducted randomized phase 3 trials have revealed that the intraperitoneal administration of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves both progression-free and overall survivals compared to an all intravenous cisplatin-based regimen. Based on very reasonable extrapolations from existing evidence-based data, a number of possible “options” can be proposed that use the intraperitoneal route for delivery of chemotherapy in this clinical setting %U https://ijgc.bmj.com/content/ijgc/18/Suppl_1/36.full.pdf